Open AccessRNA interference-based therapies for the control of atherosclerosis risk factors
Author(s) -
Sanna Kettunen,
Anna-Kaisa Ruotsalainen,
Seppo YläHerttuala
Publication year - 2022
Publication title -
current opinion in cardiology/current opinion in cardiology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.826
H-Index - 78
eISSN - 1080-787X
pISSN - 0268-4705
DOI - 10.1097/hco.0000000000000972
Subject(s) - medicine , rna interference , clinical trial , pcsk9 , bioinformatics , hyperlipidemia , inflammation , pharmacology , proprotein convertase , cholesterol , lipoprotein , endocrinology , diabetes mellitus , rna , biology , ldl receptor , gene , biochemistry
Atherosclerosis, characterized by lipid accumulation and chronic inflammation in the arterial wall, is the leading causes of death worldwide. The purpose of this article is to review the status of RNA interference (RNAi) based therapies in clinical trials for the treatment and prevention of atherosclerosis risk factors.